Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
RCT
ACE Report #6206
Ace Report Cover General Orthopaedics

WCO-IOF: Methotrexate may reduce BMD loss in patients with rheumatoid arthritis


Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

Osteoporosis in patients with rheumatoid arthritis: methotrexate compared with leflunomide treatment alone

Contributing Authors: N Ganea L Groppa E Russu

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CONFERENCE ACE REPORTS

This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

Synopsis

40 patients with active rheumatoid arthritis were randomized to receive methotrexate or leflunomide to compare treatment effects on bone loss over a 12 month period. Upon analysis, bone mineral density (BMD) loss in the methotrexate group was significantly reduced at the femoral neck, total hip, and L2-4 spine compared to the leflunomide group. BMD loss at the hand was similar between the two grou...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.